comparemela.com

VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine. BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used by BioVaxys' Lyon-based manufacturing partner, BioElpida ("BioElpida"), to validate the tumor collection protocol, cryopackaging, cryopreservation, and supply chain logistics for BVX-0918 bioproduction for prospective patients in the US and EU. Donors of ovarian cancer tumors are required to sign a patient consent form, with the tumor extraction, storage, and shipping logistics following a strict protocol developed by Biovaxys, and subjected to institutional and regulatory approval. BVX-0918 produced from the surgically removed tumor cells from HCL will be screened using the identity assays derived from the OVCAR-3 cell line recently completed by BioElpida. The identity assay will be performed on every batch of autologous ovarian cancer vaccine, and is mandatory for regulatory bodies in the EU and United States. BioVaxys President and Chief Operating Officer Kenneth Kovan stated that, "The production of BVX-0918 is a process that built on the prior successful execution of sequential steps, such as the bioproduction technology transfer to BioElpida, development of validation procedures needed to support GMP manufacturing, sterility testing for transport, hapten fixation, cryopreservation methods, antibody generation, bioburden screening, endotoxin assays, and most recently, the development of the identity assays from the OVCAR-3 cell line. With the surgically excised tumors we can now begin the final stages of the vaccine production protocol and GMP validation." BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors. A first generation single-hapten vaccine invented by BioVaxys Co-Founder and Chief Medical OfficerDavid Berd, MD, achieved positive immunological and clinical results in Phase I and Phase II human trials in over 600 patients with different tumor types, as well as having no observed toxicity in years of clinical study. These studies were conducted under an FDA-reviewed IND. A first generation autologous, haptenized vaccine was also tested by Dr. Berd in women with advanced ovarian cancer who had ceased to respond to conventional chemotherapy. The results were encouraging: In 24 patients, the median overall survival was 25.4 months with a range of 4.5-57.4 months; 8 patients survived for more than 2 years. BioVaxys has enhanced the first-generation approach by utilizing two haptens ("bi-haptenization"), which the Company believes will yield superior results. About BioVaxys Technology Corp. Based inVancouver,BioVaxys Technology Corp. (www.biovaxys.com) is aBritish Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF). ON BEHALF OF THE BOARD Signed "James Passin" James Passin, CEO +1 646 452 7054 Government & Media Relations JB&A, Inc. Davin Shinedling davin@jennibyrne.com 1 (647) 991-6447 Cautionary Statements Regarding Forward Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian andUnited Statessecurities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine.There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, del

Related Keywords

United States ,Canada ,United Kingdom ,France ,Vancouver ,British Columbia ,Frankfurt ,Brandenburg ,Germany ,British ,Canadian ,Bioelpida ,David Berd ,Davin Shinedling ,Kenneth Kovan ,Biovaxys Technology Corp ,Jba Inc ,Biovaxys Co ,Biovaxys Or Company ,Prnewswire Biovaxys Technology Corp ,Deaconess Research Institute ,Vaxys Technology ,Hospices Civils De Lyon ,Good Manufacturing Process ,Biovaxy Lyon Based ,Vaxys President ,Chief Operating Officer Kenneth Kovan ,Biovaxys Co Founder ,Chief Medical Officer ,British Columbia Registered ,Frankfurt Bourse ,Statements Regarding Forward Looking Information ,C ,June 15 ,022 Prnewswire Biovaxys Technology Corp Cse Biov Fra 5lb Otcqb Bvaxf Quot Or Company ,Nnounced Today That Its Clinical Study Collaborator Hospices Civils De Lyon In France Quot Hcl Has Surgically Excised The First Ovarian Cancer Tumors From Patients To Be Used By Biovaxys For Process Development And Manufacturing Dry Runs Of Bvx 0918 ,A Major Step Leading To The Completion Of Good Manufacturing Process Quot Gmp Production Company 39s Ovarian Cancer Vaccine Biovaxys Recently Entered Collaborations With Hcl And Deaconess Research Institute In United States Provide Surgically Debulked Tumors From Stage Iii Iv Patients Tumor Samples Both Hospitals Are Being Used By 39 Lyon Based Partner ,Ioelpida Quot Bioelpida ,O Validate The Tumor Collection Protocol ,Ryopackaging ,Cryopreservation ,Nd Supply Chain Logistics For Bvx 0918 Bioproduction Prospective Patients In The Us And Eu Donors Of Ovarian Cancer Tumors Are Required To Signa Patient Consent Form ,Ith The Tumor Extraction ,Storage ,Nd Shipping Logistics Followinga Strict Protocol Developed By Biovaxys ,Nd Subjected To Institutional And Regulatory Approval Bvx 0918 Produced From The Surgically Removed Tumor Cells Hcl Will Be Screened Using Identity Assays Derived Ovcar 3 Cell Line Recently Completed By Bioelpida Assay Performed On Every Batch Of Autologous Ovarian Cancer Vaccine ,Nd Is Mandatory For Regulatory Bodies In The Eu And United States Biovaxys President Chief Operating Officer Kenneth Kovan Stated That ,Uot The Production Of Bvx 0918 Isa Process That Built On Prior Successful Execution Sequential Steps ,Uch As The Bioproduction Technology Transfer To Bioelpida ,Evelopment Of Validation Procedures Needed To Support Gmp Manufacturing ,Terility Testing For Transport ,Apten Fixation ,Ryopreservation Methods ,Antibody Generation ,Ioburden Screening ,Ndotoxin Assays ,Nd Most Recently ,He Development Of The Identity Assays From Ovcar 3 Cell Line With Surgically Excised Tumors We Can Now Begin Final Stages Vaccine Production Protocol And Gmp Validation Quot Biovaxys 39 Platform Is Based On Established Immunological Concept That Modifying Surface Proteins Whether They Are Viral Or Tumor Haptens Makes Them More Visible To Immune System This Process Haptenization Teaches Quota Patient 39s Recognize Make Target As Foreign ,Hereby Stimulatingat Cell Mediated Immune Response Biovaxys 39 Cancer Vaccines Are Created By Extractinga Patient 39s Own Autologous Cells ,Hemically Linking Witha Hapten ,Nd Re Injecting Them Into The Patient To Induce An Immune Response Proteins Which Are Otherwise Not Immunogenic Haptenization Isa Well Known And Studied Immunotherapeutic Approach Cancer Immunotherapy Has Been Clinically Evaluated In Both Regional Disseminated Metastatic Tumorsa First Generation Single Hapten Vaccine Invented By Biovaxys Co Founder Chief Medical Officerdavid Berd ,D ,Chieved Positive Immunological And Clinical Results In Phasei Phase Ii Human Trials Over 600 Patients With Different Tumor Types ,S Well As Having No Observed Toxicity In Years Of Clinical Study These Studies Were Conducted Under An Fda Reviewed Inda First Generation Autologous ,Aptenized Vaccine Was Also Tested By Dr Berd In Women With Advanced Ovarian Cancer Who Had Ceased To Respond Conventional Chemotherapy The Results Were Encouraging 24 Patients ,He Median Overall Survival Was 25 4 Months Witha Range Of 5 57 8 Patients Survived For More Than 2 Years Biovaxys Has Enhanced The First Generation Approach By Utilizing Two Haptens Quot Bi Haptenization ,Hich The Company Believes Will Yield Superior Results About Biovaxys Technology Corp Based Invancouver ,Biovaxys Technology Corp Www Com Is Abritish Columbia Registered ,Linical Stage Biotechnology Company That Is Developing Viral And Oncology Vaccine Platforms ,S Well As Immuno Diagnostics The Company Is Advancing Vaccines For Sars Cov 2 ,Sars Cov 1 ,Nda Pan Sarbecovirus Vaccine Based On Its Haptenized Viral Protein Technology ,Nd Is Planninga Clinical Trial Of Its Haptenized Autologous Cell Vaccine Used In Combination With Anti Pd1 And Pdl1 Checkpoint Inhibitors That Will Initially Be Developed For Stage Iii Iv Ovarian Cancer Also Development Covidth ,A Diagnostic For Evaluating The Presence Or Absence Ofat Cell Immune Response To Sars Cov 2 ,He Virus That Causes Covid 19 Biovaxys Has Two Issued Us Patents ,Nd Multiple Us And International Patent Applications Related To Its Cancer Vaccines ,Antiviral Vaccines ,Nd Diagnostic Technologies Biovaxys Common Shares Are Listed On The Cse Under Stock Symbol Quot Biov And Trade Frankfurt Bourse Fra 5lb In Us Otcqb Bvaxf Behalf Of Board Signed James Passin ,Eo 1 646 452 7054 Government Amp Media Relations Jb A ,Nc Davin Shinedling Jennibyrne Com 1 647 991 6447 Cautionary Statements Regarding Forward Looking Information This Press Release Includes Certain Quot And Collectively Within The Meaning Of Applicable Canadian Andunited Statessecurities Legislation Including United States Private Securities Litigation Reform Act 1995 All ,Ther Than Statements Of Historical Fact ,Included Herein ,Without Limitation ,Tatements Relating The Future Operating Or Financial Performance Of Company ,Re Forward Looking Statements Are Frequently ,Ut Not Always ,Dentified By Words Such As Quot Expects ,Uot Anticipates Quot ,Uot Believes Quot ,Uot Intends Quot ,Uot Estimates Quot ,Uot Potential Quot ,Uot Possible Quot ,Nd Similar Expressions ,R Statements That Events ,Conditions ,R Results Quot Will ,Uot May Quot ,Uot Could Quot ,R Quot Should Occur Or Be Achieved Forward Looking Statements In This News Release Relate To ,Among Other Things ,Ompletion Of The Murine Model Study ,Egulatory Approval Fora Phasei Study Of Its Bvx 0320 Vaccine Candidate In Humans And The Overall Development Biovaxys 39 Vaccines ,Ncluding Any Haptenized Sars Cov 2 Protein Vaccine There Can Be No Assurance That Such Statements Will Prove To Accurate ,Nd Actual Results And Future Events Could Differ Materially From Those Expressed Or Implied In Such Forward Looking Statements These Reflect The Beliefs ,Pinions And Projections On The Date Statements Are Made Based Upona Number Of Assumptions Estimates ,Rimarily The Assumption That Biovaxys Will Be Successful In Developing And Testing Vaccines ,Hat ,Hile Considered Reasonable By The Company ,Re Inherently Subject To Significant Business ,Economic ,Ompetitive ,Olitical And Social Uncertainties Contingencies Including ,Rimarily But Without Limitation ,He Risk That Biovaxys 39 Vaccines Will Not Prove To Be Effective And Or Receive The Required Regulatory Approvals With Regards Business ,Here Area Number Of Risks That Could Affect The Development Its Biotechnology Products ,Ncluding ,He Need For Additional Capital To Fund Clinical Trials ,Ts Lack Of Operating History ,Ncertainty About Whether Its Products Will Complete The Long ,Omplex And Expensive Clinical Trial Regulatory Approval Process For Of New Drugs Necessary Marketing ,Ncertainty About Whether Its Autologous Cell Vaccine Immunotherapy Can Be Developed To Produce Safe And Effective Products ,Of So ,Hether Its Vaccine Products Will Be Commercially Accepted And Profitable ,The Expenses ,El ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.